Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with …
H Kameda, H Nagasawa, H Ogawa… - The Journal of …, 2005 - jrheum.org
OBJECTIVE: Acute/subacute interstitial pneumonia (A/SIP) in patients with polymyositis/dermatomyositis
(PM/DM) is frequently fatal within months despite high dose prednisolone (PSL) …
(PM/DM) is frequently fatal within months despite high dose prednisolone (PSL) …
[HTML][HTML] Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate …
…, H Yasuoka, S Hirata, H Nagasawa… - Annals of the …, 2016 - ard.bmj.com
Objective To compare the efficacy and safety between tocilizumab added to methotrexate
and tocilizumab switched from methotrexate in patients with active rheumatoid arthritis (RA). …
and tocilizumab switched from methotrexate in patients with active rheumatoid arthritis (RA). …
Time‐dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis
…, T Nanki, R Koike, H Nagasawa… - Arthritis care & …, 2012 - Wiley Online Library
Objective To investigate associations between continuous treatments with tumor necrosis
factor (TNF) antagonists and risk for developing serious infections (SIs) over 3 years in …
factor (TNF) antagonists and risk for developing serious infections (SIs) over 3 years in …
[HTML][HTML] Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from …
…, K Saito, S Hirata, K Amano, H Nagasawa… - Arthritis research & …, 2015 - Springer
Introduction The objective of this study was to directly compare the safety of tocilizumab (TCZ)
and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice. …
and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice. …
Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study
…, K Amano, D Hoshi, M Nawata, H Nagasawa… - …, 2011 - academic.oup.com
Objectives. To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical
practice. Methods. We observed 232 consecutive RA patients who began tocilizumab in …
practice. Methods. We observed 232 consecutive RA patients who began tocilizumab in …
Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells
…, K Amano, T Okayama, H Nagasawa… - Biochemical and …, 2009 - Elsevier
Introduction of biologics, such as infliximab, to the therapy of rheumatoid arthritis (RA) patients
has revolutionized the treatment of this disease. However, biomarkers for predicting the …
has revolutionized the treatment of this disease. However, biomarkers for predicting the …
Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis
…, J Tamaru, S Itoyama, H Nagasawa… - Leukemia & …, 2012 - Taylor & Francis
Despite numerous attempts to uncover the mechanism of other iatrogenic immunodeficiency-associated
lymphoproliferative diseases (OIIA-LPDs), this mechanism remains poorly …
lymphoproliferative diseases (OIIA-LPDs), this mechanism remains poorly …
Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk …
…, K Saito, Y Tanaka, H Nagasawa… - Modern …, 2012 - Taylor & Francis
Objectives The association of anti-tumor necrosis factor therapy with opportunistic infections
in rheumatoid arthritis (RA) patients has been reported. The goal of this study was to clarify …
in rheumatoid arthritis (RA) patients has been reported. The goal of this study was to clarify …
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different …
…, H Yamazaki, R Koike, H Nagasawa… - Annals of the …, 2012 - ard.bmj.com
Objective To compare reasons for discontinuation and drug retention rates per reason
among anticytokine therapies, infliximab, etanercept and tocilizumab, and the risk of …
among anticytokine therapies, infliximab, etanercept and tocilizumab, and the risk of …
Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with …
…, A Shibata, Y Okada, H Takei, H Nagasawa… - Clinical …, 2017 - Springer
The purpose of this study is to report the efficacy and safety of a combination of tocilizumab (TCZ)
and high-dose corticosteroid (CS) in two patients with microscopic polyangiitis (MPA) …
and high-dose corticosteroid (CS) in two patients with microscopic polyangiitis (MPA) …